NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Amicus Therapeutics Appoints Senior VP, International
Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has appointed David Allsop as senior VP, international. He is responsible for Amicus’ international organizational build out, and is leading international commercial and market access activities for migalastat monotherapy for Fabry disease.
Before joining Amicus, Mr. Allsop was instrumental in building Biogen’s international commercial organization over the last 17 years.
Dr. Lakhmir Chawla
La Jolla Pharmaceutical Names Chief Medical Officer
La Jolla Pharmaceutical, which is developing innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, has appointed Lakhmir Chawla, M.D., chief medical officer.
Dr. Chawla is currently an associate professor of medicine at the George Washington University, where he has dual appointments in the Department of Anesthesiology and Critical Care Medicine and in the Department of Medicine, Division of Renal Diseases and Hypertension. Dr. Chawla is also currently the chief of the division of intensive care medicine at the Washington, D.C., Veterans Affairs Medical Center.
Blend Therapeutics Appoints President and CEO
Blend Therapeutics, a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, has appointed Drew Fromkin president and CEO.
Mr. Fromkin previously served as president and CEO of Clinical Data, until its acquisition by Forest Laboratories.
Dr. Jeremy Levin
Ovid Therapeutics Names CEO
Ovid Therapeutics, a privately held biopharmaceutical company focused on developing therapies for rare and orphan diseases of the brain, has appointed Jeremy Levin, BMBS, as CEO. Dr. Levin has served as chairman of Ovid since 2014 and will continue to serve in this role.
Dr. Levin has more than 25 years of experience in the global pharmaceutical industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide. Most recently, Dr. Levin served as president and CEO of Teva Pharmaceutical Industries.
Synta Names President, CEO
Synta Pharmaceuticals has promoted Chen Schor from executive VP, chief operating officer, to president and CEO. Mr. Schor replaces Anne Whitaker, who is stepping down from her roles at Synta.
Mr. Schor has more than 15 years of leadership experience in biotechnology, medical devices, business development, and private equity.
Voyager Therapeutics Announces Promotion
Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the appointment of Jeff Goater, former VP of business development, to senior VP, finance and business development.
In this new role, Mr. Goater is responsible for overseeing finance, business development, and investor and public relations activities across the company.
Interleukin Genetics Appoints CEO
Interleukin Genetics has named Mark Carbeau as CEO. Mr. Carbeau is a transformative healthcare leader who brings to Interleukin more than three decades of business expertise in the life-science industries, with a proven track record of building high-growth diagnostic and pharmaceutical businesses.
Before joining Interleukin, Mr. Carbeau was co-founder and CEO of Diagnostyx, a technology-based healthcare company focused on intelligent drug infusion systems.
Palio Passes Leadership Torch
Palio, an inVentiv Health advertising agency, in announcing that Chief Creative Global Officer Guy Mastrion has departed the agency, has named Michael Austin and Louis Massaia to lead the agency’s bicoastal creative teams in California (Irvine and Santa Monica) and New York (New York City and Saratoga Springs).
Mr. Austin and Mr. Massaia have worked together for years at top-tier agencies, most recently as senior VP/creative directors at The CementBloc.
CEO of West Pharmaceutical Services Named
West Pharmaceutical Services, a provider of solutions for injectable drug administration, has appointed Eric M. Green as the company’s CEO succeeding Donald E. Morel, Jr., Ph.D. Mr. Green joins West from Sigma-Aldrich Corp., where he has served as executive VP and president of the research markets business unit since 2013.
For bonus content go to bit.ly/PV0615-Pool